Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Conditions
Brief summary
Primary Objective: \- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab Secondary Objectives: * To determine the safety and tolerability of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with indolent Hon-Hodgkin Lymphoma (iNHL) Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) * To determine the pharmacokinetics (PK) of SAR245409, bendamustine and rituximab when used in combination in subjects with iNHL, MCL or CLL * To determine the pharmacodynamic (PD) effects of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with iNHL, MCL or CLL * To determine the antitumor activity of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with iNHL, MCL or CLL
Detailed description
All subjects will take SAR245409 twice daily. All subjects will receive SAR245409 as long as there is clinical benefit. Combination therapy with SAR245409, bendamustine and rituximab , will be administered over a 28 day cycle for up to 6 to 8 cycles. Subjects receiving the doublet combination , SAR245409 plus rituximab will receive weekly rituximab for 4 - 8 weeks. Monthly Rituximab may be continued beyond 8 weeks.
Interventions
DRUGSAR245409
Pharmaceutical form:capsule Route of administration: oral
Sponsors
Sanofi
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A confirmed diagnosis of indolent non-Hodgkin lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia * Evaluable disease or measurable disease * Transfusion independent * Able to take oral medication * Male and Female subjects \> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Women of childbearing potential using adequate contraception
Exclusion criteria
* Prior therapy with a PI3K, mTOR or dual PI3K/mTOR inhibitor resulting in adverse events necessitating treatment discontinuation * Eligible for a hematopoietic stem cell transplant (HSCT) * The subject has received investigational or non-investigational cytotoxic chemotherapy (i.e., cyclophosphamide), small molecule cancer therapy (i.e., imatinib), biologic cancer therapies other than rituximab (i.e., alemtuzumab, cytokines, vaccines or other monoclonal antibodies) hormonal therapy, radio- or immuno- conjugates (e.g. ibritumomab tiuxetan, tositumomab) or immunosuppressants to treat malignancy within 4 weeks prior to Cycle 1, Day 1 * Radiation therapy within 2 weeks prior to Cycle 1, Day 1 * Autologous Hematopoietic Stem Cell Transplant (HSCT) within the past 16 weeks * Prior allogeneic HSCT * Active central nervous system (CNS) metastases or leptomeningeal involvement * Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (anti-HCV) * Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection * Active peptic ulcer disease requiring treatment with proton pump inhibitors (e.g. pantoprazole) or Type 2 histamine antagonists (e.g. cimetidine) * Diagnosis or treatment for another malignancy within 3 years of enrollment with the exception of complete resection of basal cell or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy * Inadequate bone marrow function * Abnormal liver function * Abnormal renal function * Abnormal coagulation The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification Of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) | 4 weeks to 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (Cmax) of SAR245409 | up to 2 months |
| Pharmacokinetics (tmax) of SAR245409 | up to 2 months |
| Pharmacokinetics (AUC0-12h) of SAR245409 | up to 2 months |
| Pharmacokinetics (Ctrough) of SAR245409 | up to 2 months |
| Pharmacokinetics (AUC) of bendamustine | up to 2 months |
| Pharmacokinetics (AUClast) of bendamustine | up to 2 months |
| Pharmacokinetics (Ceoi) of bendamustine | up to 2 months |
| Number of subjects with treatment emergent adverse events | Time from receiving first dose of SAR245409 until 30 days after the last dose |
| Pharmacokinetics (Cl) of bendamustine | up to 2 months |
| Pharmacokinetics (Vss) of bendamustine | up to 2 months |
| Pharmacokinetics (AUC0-7h) of rituximab | up to 2 months |
| Pharmacokinetics (Ceoi) of rituximab | up to 2 months |
| Pharmacokinetics (tmax) of rituximab | up to 2 months |
| Efficacy as determined by objective response rate (ORR) | up to 4 years |
| Pharmacokinetics (tmax) of bendamustine | up to 2 months |
Countries
United States
Outcome results
None listed